Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Sunny Jim who wrote (14093)	2/3/1998 7:53:00 AM
From: tonyt	Respond to of 32384

> If biotechs are a great bargain, why aren't the big pharmas buying them? High Risk. The manage risk by partnering with more than one company.

To: Sunny Jim who wrote (14093)	2/3/1998 8:08:00 AM
From: Henry Niman	Respond to of 32384

CNBC just had Michael Waldholtz from the WSJ on. He reiterated much of what had been said yesterday or printed this morning. His overall view was that at the present time there is a bit of a lag in new blockbusters. Many of the current big sellers were brought to market in the 80's or early 90's and now they are going off patent. The merger mania is being driven in part by projected costs to develop drugs discovered through genomics. He indicated that JNJ, MRK, and PFE would not be looking for merger partners. They consider such moves as too distracting. He noted that MRK's AIDS drugs were bringing in more revenue than initially expected, and PFE's impotence drug may be a blockbuster, but it was a wild card because the market wasn't well defined.

To: Sunny Jim who wrote (14093)	2/3/1998 8:22:00 AM
From: tonyt	Respond to of 32384

> The merger mania is being driven in part by projected costs to develop drugs > discovered through genomics. He indicated that JNJ, MRK, and PFE would not be > looking for merger partners. They consider such moves as too distracting. Interesting.....